Literature DB >> 23478301

Rapid and efficient reprogramming of human fetal and adult blood CD34+ cells into mesenchymal stem cells with a single factor.

Xianmei Meng1, Rui-Jun Su, David J Baylink, Amanda Neises, Jason B Kiroyan, Wayne Yuk-Wai Lee, Kimberly J Payne, Daila S Gridley, Jun Wang, K-H William Lau, Gang Li, Xiao-Bing Zhang.   

Abstract

The direct conversion of skin cells into somatic stem cells has opened new therapeutic possibilities in regenerative medicine. Here, we show that human induced mesenchymal stem cells (iMSCs) can be efficiently generated from cord blood (CB)- or adult peripheral blood (PB)-CD34(+) cells by direct reprogramming with a single factor, OCT4. In the presence of a GSK3 inhibitor, 16% of the OCT4-transduced CD34(+) cells are converted into iMSCs within 2 weeks. Efficient direct reprogramming is achieved with both episomal vector-mediated transient OCT4 expression and lentiviral vector-mediated OCT4 transduction. The iMSCs express MSC markers, resemble bone marrow (BM)-MSCs in morphology, and possess in vitro multilineage differentiation capacity, yet have a greater proliferative capacity compared with BM-MSCs. Similar to BM-MSCs, the implanted iMSCs form bone and connective tissues, and are non-tumorigenic in mice. However, BM-MSCs do not, whereas iMSCs do form muscle fibers, indicating a potential functional advantage of iMSCs. In addition, we observed that a high level of OCT4 expression is required for the initial reprogramming and the optimal iMSC self-renewal, while a reduction of OCT4 expression is required for multilineage differentiation. Our method will contribute to the generation of patient-specific iMSCs, which could have applications in regenerative medicine. This discovery may also facilitate the development of strategies for direct conversion of blood cells into other types of cells of clinical importance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23478301      PMCID: PMC3641600          DOI: 10.1038/cr.2013.40

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  45 in total

1.  Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors.

Authors:  Sayaka Sekiya; Atsushi Suzuki
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

2.  Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors.

Authors:  Pengyu Huang; Zhiying He; Shuyi Ji; Huawang Sun; Dao Xiang; Changcheng Liu; Yiping Hu; Xin Wang; Lijian Hui
Journal:  Nature       Date:  2011-05-11       Impact factor: 49.962

Review 3.  Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide.

Authors:  Federico Mosna; Luc Sensebé; Mauro Krampera
Journal:  Stem Cells Dev       Date:  2010-10       Impact factor: 3.272

4.  Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.

Authors:  Jianming Tan; Weizhen Wu; Xiumin Xu; Lianming Liao; Feng Zheng; Shari Messinger; Xinhui Sun; Jin Chen; Shunliang Yang; Jinquan Cai; Xia Gao; Antonello Pileggi; Camillo Ricordi
Journal:  JAMA       Date:  2012-03-21       Impact factor: 56.272

Review 5.  Role of mesenchymal stem cell therapy in Crohn's disease.

Authors:  Jignesh Dalal; Kimberly Gandy; Jos Domen
Journal:  Pediatr Res       Date:  2012-02-08       Impact factor: 3.756

6.  Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs.

Authors:  David R Deyle; Iram F Khan; Gaoying Ren; Pei-Rong Wang; Jordan Kho; Ulrike Schwarze; David W Russell
Journal:  Mol Ther       Date:  2011-10-25       Impact factor: 11.454

7.  Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone.

Authors:  Xianmei Meng; Amanda Neises; Rui-Jun Su; Kimberly J Payne; Linda Ritter; Daila S Gridley; Jun Wang; Matilda Sheng; K-H William Lau; David J Baylink; Xiao-Bing Zhang
Journal:  Mol Ther       Date:  2011-11-22       Impact factor: 11.454

8.  Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors.

Authors:  Masaki Ieda; Ji-Dong Fu; Paul Delgado-Olguin; Vasanth Vedantham; Yohei Hayashi; Benoit G Bruneau; Deepak Srivastava
Journal:  Cell       Date:  2010-08-06       Impact factor: 41.582

Review 9.  Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products.

Authors:  Yunjoon Jung; Gerhard Bauer; Jan A Nolta
Journal:  Stem Cells       Date:  2012-01       Impact factor: 6.277

10.  Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures.

Authors:  Bin-Kuan Chou; Prashant Mali; Xiaosong Huang; Zhaohui Ye; Sarah N Dowey; Linda Ms Resar; Chunlin Zou; Y Alex Zhang; Jay Tong; Linzhao Cheng
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

View more
  21 in total

Review 1.  From Skeletal Development to Tissue Engineering: Lessons from the Micromass Assay.

Authors:  Darinka D Klumpers; David J Mooney; Theo H Smit
Journal:  Tissue Eng Part B Rev       Date:  2015-06-25       Impact factor: 6.389

2.  Direct Conversion of Cord Blood CD34+ Cells Into Neural Stem Cells by OCT4.

Authors:  Wenbin Liao; Nick Huang; Jingxia Yu; Alexander Jares; Jianchang Yang; Gary Zieve; Cecilia Avila; Xun Jiang; Xiao-Bing Zhang; Yupo Ma
Journal:  Stem Cells Transl Med       Date:  2015-05-13       Impact factor: 6.940

3.  Semaphorin 3A induces mesenchymal-stem-like properties in human periodontal ligament cells.

Authors:  Naohisa Wada; Hidefumi Maeda; Daigaku Hasegawa; Stan Gronthos; Peter Mark Bartold; Danijela Menicanin; Shinsuke Fujii; Shinichiro Yoshida; Atsushi Tomokiyo; Satoshi Monnouchi; Akifumi Akamine
Journal:  Stem Cells Dev       Date:  2014-02-10       Impact factor: 3.272

4.  Generation of Integration-free Induced Pluripotent Stem Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors.

Authors:  Wei Wen; Jian-Ping Zhang; Wanqiu Chen; Cameron Arakaki; Xiaolan Li; David Baylink; Gary D Botimer; Jing Xu; Weiping Yuan; Tao Cheng; Xiao-Bing Zhang
Journal:  J Vis Exp       Date:  2017-01-01       Impact factor: 1.355

Review 5.  A review of literature: role of long noncoding RNA TPT1-AS1 in human diseases.

Authors:  Yi Li; Fulei Li; Zongzong Sun; Juan Li
Journal:  Clin Transl Oncol       Date:  2022-09-16       Impact factor: 3.340

6.  Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells.

Authors:  K Pinz; H Liu; M Golightly; A Jares; F Lan; G W Zieve; N Hagag; M Schuster; A E Firor; X Jiang; Y Ma
Journal:  Leukemia       Date:  2015-11-03       Impact factor: 11.528

7.  HDAC inhibitors improve CRISPR-mediated HDR editing efficiency in iPSCs.

Authors:  Jian-Ping Zhang; Zhi-Xue Yang; Feng Zhang; Ya-Wen Fu; Xin-Yue Dai; Wei Wen; Beldon Zhang; Hannah Choi; Wanqiu Chen; Meredith Brown; David Baylink; Lei Zhang; Hongyu Qiu; Charles Wang; Tao Cheng; Xiao-Bing Zhang
Journal:  Sci China Life Sci       Date:  2021-01-06       Impact factor: 6.038

Review 8.  Fate of graft cells: what should be clarified for development of mesenchymal stem cell therapy for ischemic stroke?

Authors:  Yuka Ikegame; Kentaro Yamashita; Shigeru Nakashima; Yuichi Nomura; Shingo Yonezawa; Yoshitaka Asano; Jun Shinoda; Hideaki Hara; Toru Iwama
Journal:  Front Cell Neurosci       Date:  2014-10-21       Impact factor: 5.505

9.  Efficient generation of integration-free ips cells from human adult peripheral blood using BCL-XL together with Yamanaka factors.

Authors:  Rui-Jun Su; David J Baylink; Amanda Neises; Jason B Kiroyan; Xianmei Meng; Kimberly J Payne; Benjamin Tschudy-Seney; Yuyou Duan; Nancy Appleby; Mary Kearns-Jonker; Daila S Gridley; Jun Wang; K-H William Lau; Xiao-Bing Zhang
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

Review 10.  Cellular reprogramming of human peripheral blood cells.

Authors:  Xiao-Bing Zhang
Journal:  Genomics Proteomics Bioinformatics       Date:  2013-09-21       Impact factor: 7.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.